Specialized generic focus Stockton Labs specializes in developing ANDA generic pharmaceuticals and operates a CMO liquid manufacturing facility in San Diego, positioning them to accelerate access to affordable generics for smaller or overlooked market needs.

Vertical integration Owning a dedicated liquid manufacturing CMO provides end-to-end control over formulation, packaging, and repackaging for retail and unit-dose products, enabling faster time-to-market and potential price competitiveness.

FDA approved opportunity Recent launch of Sdamlo, the first FDA-approved amlodipine oral solution powder in the U.S., signals regulatory credibility and a pathway to expand portfolio with other approved generic formulations.

Growth potential With reported revenue in the mid tens of millions and a lean team, Stockton Labs can scale through strategic partnerships, contract manufacturing deals, and expansion into additional generic liquid formulations for high-demand cardiovascular and common therapeutic classes.

Competitive positioning Smaller, agile player with a focus on neglected generic opportunities can collaborate with larger manufacturers seeking to accelerate product approvals or fill gaps in their generic pipelines, offering a complementary route to market for bigger peers.